Biogen Idec

2Q Revenues: $773 million (+17%)

2Q Earnings: $186 million (net loss of $171 million in 2Q2006)

YTD Revenues: $1.5 billion (+17%)

YTD Earnings: $318 million (net loss of $48 million in 2Q2006)

Comments: Avonex sales rose 8% to $462 million, Rituxan was up 12% to $231 million and Tysabri brought in $48 million in sales to BI ($72 million in total sales, with the remainder going to partner Elan). The company announced that there are 14,000 MS patients using Tysabri.

News from our sister sites